Received Mar 16, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 79MR9 | — |
patients have received only the diluent portion of Shingrix; patients have received only the diluent portion of Shingrix; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate preparation of medication in a 63-year-old male patient who received Herpes zoster (Shingrix) (batch number 79MR9, expiry date 26-AUG-2027) for prophylaxis. On 12-FEB-2026, the patient received Shingrix. On 12-FEB-2026, an unknown time after receiving Shingrix, the patient experienced inappropriate preparation of medication (Verbatim: patients have received only the diluent portion of Shingrix) and inappropriate dose of vaccine administered (Verbatim: patients have received only the diluent portion of Shingrix). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK receipt date: 10-MAR-2026 The reporter mentioned that patient had received only the diluent portion of Shingrix. This case is one of the link cases of US2026033731 and US2026033733 reported by the same reporter for different patients.; Sender's Comments: US-GSK-US2026033731:Same reporter/Different patient US-GSK-US2026033733:Same reporter/Different patient